It’s often said that the only constant is change. Here at the Fogarty Institute, we embrace that sentiment because in the world of medtech, change is inevitable to continue to enhance patient care. That’s why we are delighted with recent advances in funding – while the funding environment can be challenging, the industry has demonstrated resilience and agility as startups seek to get innovative devices to market.
What started as a vision to use a mobile makerspace as a tool to inspire young, chronically ill patients to learn, create and innovate – and help make lengthy hospital stays more palatable – is now becoming a reality, thanks to the generous support of Sheri Sobrato Brisson, a long-time supporter of seriously and chronically ill children,
With luminaries such as Joe Biden, Bill Gates and Anne Wojcicki as keynote speakers, the J.P. Morgan Healthcare conference continues to be one of the most prominent events of its kind. This January, it was once again hosted in San Francisco, widely considered one of the meccas of the medtech industry.
Lower-cost, more-effective treatments are the hallmark of many Fogarty Institute companies, and that is the principle Healyx is living up to with its device that provides gold standard care for a chronic problem at a significant cost reduction.
Non-healing wounds are a critical global issue, with over eight million Medicare patients afflicted at an annual cost of $31.7 billion in the U.S.
A former Stanford Biodesign Fellow and Fogarty Institute entrepreneur, 32-year-old Holly Rockweiler has already had remarkable accomplishments early in her career, fluently moving her startup to the next level.
Most notably, Holly has parlayed Madorra’s impressive study results into securing funding, including winning several pitching competitions, despite the chronically challenging medtech fundraising environment.
When a cardiovascular intervention is called for, a less-invasive solution is always preferred – which is why percutaneous procedures, such as transcatheter aortic valve replacement (TAVR) and endovascular aneurysm repair (EVAR) are on the rise.
But this trend hasn’t been without its drawbacks, as cardiologists and surgeons are now faced with the challenge of closing relatively large femoral access sites – ranging from three to eight millimeters in size – that are required to conduct these procedures.
Often referred to as the “second brain,” the gut is garnering increased attention as mounting evidence shows the key role it plays far beyond digesting food in influencing our moods and general health. G-Tech Medical, a Fogarty Institute company, is playing a critical role in helping to better understand the complexities of our gut and its 500 million neurons.